A r t i c l e s The shortage of organs available for transplant to terminally ill patients represents a major worldwide medical, social and economic challenge. An alternative approach to whole-organ transplant involves the transplantation of cells to regenerate failing organs 1, 2 . However, orthotopic cell-based therapy directed at a diseased organ may not be feasible for many reasons, ranging from a possible lack of an appropriate environment in cirrhotic and fibrotic liver during end-stage disease to the lack of a thymus in complete DiGeorge syndrome [3] [4] [5] . Consequently, a crucial requirement of cell-based therapy for these patients is to establish an optimal in vivo site for cell and tissue transplantation to restore organ functions 6, 7 .
The lymph node is a key organ of the mammalian immune system that has evolved to mount an immediate and orchestrated response against invading pathogens. The lymph node acts as a checkpoint where migrating T and B cells may encounter foreign antigens 8, 9 . If a foreign antigen is identified, T cells undergo rapid cell division and also signal for help and recruit additional T cells 8, 9 . To accommodate this sudden increase in cell number, lymphocytes need a special environment, which the lymph node provides.
Interestingly, the lymph node is also one of the first clinically observed sites of most cancer metastasis. Selected cancer cells will often migrate away from a primary tumor and colonize the lymph node 10 . Lymphatic vessels are designed to facilitate the uptake of surrounding fluid and cells, which are then transported to a nearby lymph node 10 . Therefore, malignant tumor cells take advantage of this route normally traveled by immune cells. On arrival in the lymph node, tumor cells can survive, perhaps because the architecture of the lymph node provides direct access through the high endothelial venules to essential nutrients and growth factors found in the blood. The lymph node also contains fibroblastic reticular cells and other stromal cells that secrete chemokines to enhance cell recruitment and survival 8, 9, 11 .
Because lymph nodes support normal immune function as well as the survival of metastatic tumor cells, they might also promote the survival and expansion of healthy cells and tissues. Healthy cell and tissue growth in lymph nodes would provide a new approach for cell therapies in regenerative medicine.
Here we test the hypothesis that when transplanted directly into the lymph nodes of mice, three distinct healthy cell types engraft and show ectopic organ functions in vivo. Previously, our lab showed that primary hepatocytes injected intraperitoneally into mice lacking fumarylacetoacetate hydrolase (a mouse model of tyrosinemia type I) migrate and colonize the host abdominal lymphatics and restore hepatic functions 12 . Here we show that hepatocytes injected directly into a single jejunal, popliteal, axillary or periportal lymph node generate an ectopic hepatic mass and rescue mice from lethal liver failure. Furthermore, thymic tissue injected into single jejunal lymph nodes of athymic nude mice generates functional ectopic thymuses. Additionally, pancreatic islets transplanted into single jejunal lymph nodes of streptozotocin-induced diabetic mice engraft and secrete insulin to normalize glucose concentrations. These three independent results support the proof of concept that the lymph node provides a hospitable environment for normal cell engraftment and reveal a new approach to consider for future ectopic tissue and organ regeneration.
RESULTS

Direct injection of hepatocytes into the lymph node
We targeted single jejunal lymph nodes in the abdominal cavities of C57BL/6 wild-type mice, an area that we selected because it is easily accessible and relatively large 13 . After injection of 100,000-500,000 syngeneic primary hepatocytes, the lymph nodes enlarged slightly and had no visible leakage, as evidenced by staining with Evans blue dye ( Fig. 1a) . One day after injection, syngeneic luciferase-expressing hepatocytes remained in the lymph nodes, as determined by in vivo imaging of luciferase ( Fig. 1b) . In contrast, splenic and intraperitoneal injection of hepatocytes resulted in the rapid dispersion of cells to the mouse lymph node as an ectopic transplantation site for multiple tissues
Junji Komori 1,3 , Lindsey Boone 1,3 , Aaron DeWard 1,3 , Toshitaka Hoppo 1,2 & Eric Lagasse 1
Cell-based therapy has been viewed as a promising alternative to organ transplantation, but cell transplantation aimed at organ repair is not always possible. Here we show that the mouse lymph node can support the engraftment and growth of healthy cells from multiple tissues. Direct injection of hepatocytes into a single mouse lymph node generated enough ectopic liver mass to rescue the survival of mice with lethal metabolic disease. Furthermore, thymuses transplanted into single lymph nodes of athymic nude mice generated functional immune systems that were capable of rejecting allogeneic and xenogeneic grafts. Additionally, pancreatic islets injected into the lymph nodes of diabetic mice restored normal glucose control. Collectively, these results suggest the practical approach of targeting lymph nodes to restore, maintain or improve tissue and organ functions.
A r t i c l e s the liver and throughout the abdominal cavity, respectively ( Fig. 1b) . One week after transplant, syngeneic GFP + hepatocytes were distributed mainly in the subcapsular sinus of the lymph nodes but were not present in the lymph node follicles or germinal centers ( Fig. 1c) . Additionally, the hepatocytes rapidly formed patches of hepatic tissue expressing E-cadherin ( Fig. 1d) . This hepatocyte-to-hepatocyte attachment may help retain hepatocytes within the site of transplantation 14 . Furthermore, the cell trafficking molecule sphingosine-1phosphate receptor 1 (S1PR1), which is necessary for the egress of B and T cells from lymph nodes 15, 16 , was not present on hepatocytes in the lymph nodes. Conversely, CCR7, a molecule known to control the migration of memory T cells and/or tumor cells into the lymph nodes 17 , was expressed by hepatocytes in the lymph nodes ( Fig. 1d) .
These observations suggest a potential mechanism of retention of healthy hepatocytes in the lymph node.
To assess whether the engrafted hepatocytes in the lymph nodes proliferate in response to growth stimuli in C57BL/6 wild-type recipient mice, we performed partial hepatectomy (PHx) 1 week after syngeneic hepatocyte injection into the lymph nodes and added bromodeoxyuridine (BrdU) to the drinking water of the recipient mice. PHx is a physiologically relevant method of stimulating hepatocyte growth 18 . We analyzed BrdU incorporation in the lymph node-engrafted hepatocytes 2 weeks after injection and compared the result to that in mice that were not subjected to PHx. The number of GFP-expressing hepatocytes and the percentage of BrdU + hepatocytes in the lymph nodes of the mice subjected to PHx were significantly higher than those in d GFP hepatocytes in lymph node S1PR1 S1PR1 GFP S1PR1 GFP S1PR1 GFP Top middle to bottom right, immunofluorescent staining of frozen lymph node serial sections with monoclonal antibodies (mAbs) (red) to ER-TR7 (reticular fibroblasts), LYVE-1 (lymphatic vessels), PNAd (high endothelial venules), B220 (B cells) and CD4/CD8 (CD4 T and CD8 T cells) with the presence of GFP + hepatocytes (green). Dotted lines indicate the lymph node boundary. Scale bars, 100 µm. (d) Immunofluorescent staining of donor GFP + hepatocytes (green) in jejunal lymph nodes 1 week after transplantation. Shown are serial sections stained with mAbs (red) to E-cadherin (E-Cad), C-C chemokine receptor type 7 (CCR7) and S1PR1, as well as native liver sections stained as controls (right). In native liver, CCR7 (red) was co-stained with dipeptidyl peptidase-4 (DPPIV) (green). All sections were counterstained with Hoechst 33342 (blue). Scale bars, 100 µm. (e) Proliferation of engrafted hepatocytes in lymph nodes after partial hepatectomy (PHx). Paraffin sections of injected lymph nodes and corresponding native liver 1 and 2 weeks (1W and 2W, respectively) after transplantation stained for GFP (1 and 2 weeks after transplantation) and BrdU (2 weeks after transplantation) and revealed by peroxidase (brown cytoplasmic and brown nuclei staining, respectively). Sections were counterstained with hematoxylin. Yellow outlines mark small populations of GFP + hepatocytes. The bar graphs show the number of GFP + hepatocytes and the percentage of BrdU + hepatocytes per section after immunostaining at 2 weeks after transplantation in mice with or without PHx.*P < 0.05, **P < 0.0001. Data (mean ± s.e.m.) are representative of one experiment with three to five mice per group. The experiment was repeated twice. Scale bars, 100 µm. npg A r t i c l e s the mice not subjected to PHx (Fig. 1e) , indicating that hepatocytes in the lymph nodes respond to growth stimuli after PHx.
A functional ectopic liver in the lymph node Next, we asked whether transplantation of syngeneic hepatocytes into single jejunal lymph nodes of Fah −/− tyrosinemic mice [19] [20] [21] , a model of lethal metabolic liver failure, would induce hepatocyte proliferation. Twelve weeks after hepatocyte injection into the lymph nodes, the mice were rescued from lethal liver failure by the newly hepatized growth in the jejunal lymph nodes (Fig. 2) . Hepatocyte engraftment was localized to the transplanted lymph nodes and was not present in other lymph nodes or the native liver ( Fig. 2a ), suggesting that a lymphatic distribution of hepatocytes did not occur. The 'hepatized' lymph nodes were composed mostly of newly formed liver tissue containing Fah + GFP + hepatocytes but also included remnants of the lymphatic system, as revealed by surrounding LYVE1 + lymphatic endothelial cells (Fig. 2b) . The lymph nodes were transformed into hepatic organoids composed of characteristically cuboidal hepatocytes but with the absence of a biliary system 12 . To define the hepatized lymph node microarchitecture, we stained recipient lymph nodes for ER-TR7, a marker of fibroblastic reticular cells (FRCs), dipeptidyl peptidase-4 (DPP IV), a marker for brush borders of hepatocytes and bile canaliculi organization, and glutamine synthetase, a marker of zonality for hepatocytes surrounding the terminal hepatic venules 22 (Fig. 2b) . GFP + hepatocytes resided in cellular proximity with ER-TR7 + FRCs. FRCs are known to have a crucial role in establishing the reticular network, as well as in regulating immune function 11, 23 . Similar to what is observed in normal liver anatomy, DPP IV was localized throughout the hepatized lymph nodes. Moreover, we identified glutamine synthetase-positive hepatocytes surrounding some of the hepatic veins in the newly formed liver tissues. Notably, we observed survival of the mice (Fig. 2c ) and long-term persistence (over 25 weeks) of the graft after transplantation to the lymph nodes ( Fig. 2a) , and we found no immune responsiveness to the grafts, as indicated by the presence of very few lymphocytes and macrophages around the transplantation zones ( Supplementary Fig. 1 ).
We then tested whether this transplantation method is effective in other lymph nodes throughout the body, as all lymph nodes share a common histological architecture 9, 13, 24 . We injected syngeneic hepatocytes into single extra-abdominal axillary or popliteal lymph nodes in Fah −/− mice ( Fig. 2a) . Similar to the results from the intraabdominal jejunal lymph node injection, we observed a single, large, hepatized lymph node several weeks after cell transplantation, which subsequently rescued mice from lethal liver failure ( Fig. 2c) . In wild-type mice, a jejunal lymph node weighs around A r t i c l e s 25 ± 3 mg (mean ± s.d.), whereas a popliteal or axillary lymph node weighs 3 ± 1 mg (n = 5). Because the jejunal lymph node is the largest lymph node in the mouse, it was easier to inject, and injection at this site led to a higher survival rate ( Fig. 2c) . Furthermore, when we compared the mass of hepatic tissue generated in the intra-abdominal jejunal lymph nodes to those generated in the extra-abdominal axillary and popliteal lymph nodes, we found no statistical differences, indicating no tissue growth advantage between these three lymph nodes (Fig. 2d) . Transplantation of hepatocytes into periportal lymph nodes, one of the closest lymph nodes to the liver, also resulted in large hepatized lymph nodes and rescued the recipient mice from lethal liver disease. However, transplantation of lymph nodes closer to the liver did not seem to be beneficial for the experimental outcome when compared with the other transplanted lymph nodes (Fig. 2d) .
Thus far, all transplantations used syngeneic donor and recipient mice. Because lymph nodes perform a central function for allogeneic recognition 25 , we next tested whether successful engraftment is possible in allogeneic lymph nodes. We injected C57BL/6 GFP + hepatocytes into the liver (through splenic injection) or into the lymph nodes of 129sv Fah −/− recipient mice. 129sv and C57BL/6 mice share the major histocompatibility complex haplotype H2 b but differ in their minor histocompatibility antigens and are considered allogeneic 26, 27 . Whereas C57BL/6 hepatocytes transplanted into 129sv Fah −/− recipients did not engraft ( Fig. 2e) , blocking the co-stimulation pathways CD28-B7 (blocked by CTLA4-Ig) and CD40-CD40L (blocked by MR1) 28, 29 in the 129sv Fah −/− recipients facilitated successful engraftment of C57BL/6 GFP + hepatocytes injected into either the spleen or the lymph node (Fig. 2e) . This result shows that the immune reaction to transplanted cells in the lymph nodes is not stronger or faster compared to the reaction to cells transplanted in another site.
A functional ectopic thymus in the lymph node Using a similar approach, we asked whether de novo thymus function could be generated in the lymph nodes of athymic mice. We harvested thymuses from newborn C57BL/6 GFP + transgenic mice and minced and injected them directly into the jejunal lymph nodes or under the kidney capsules of athymic BALB/c nude mice. After 1 month, we analyzed the blood of the recipient mice by flow cytometry for the presence of recipient (GFP − ) single-positive CD4 + and CD8 + T cells. Thymic transplant into the lymph node (LN-Tx nude mice) or under the kidney capsule (KC-Tx nude mice) generated circulating recipient single-positive CD4 + and CD8 + T cells ( Fig. 3a and Supplementary Fig. 2 ). Ten months after transplantation, single-positive CD4 + and CD8 + T cells were still present in the peripheral blood, indicating long-term thymic engraftment in the lymph nodes (Supplementary Fig. 3) . Notably, transplantation of a thymic single-cell suspension also resulted in the presence of singlepositive CD4 + and CD8 + T cells, although to a lesser degree than did transplantation of minced thymic tissues ( Supplementary Table 1 ). We used newborn GFP + mice as a source of donor thymuses because they contain a minimal amount of mature thymocytes. In fact, less than 6% (n = 3/54) of the recipient mice showed any donor GFP + T-cell contamination in the blood 1 month after transplant when measured by flow cytometry (data not shown). We excluded these three mice from further studies.
We then harvested the ectopic thymuses for further characterization of the engraftment. GFP + epithelial thymic cells remained within the injected lymph nodes and were organized into an epithelial thymic structure (Fig. 3b) . Previously, thymic epithelia have been distinguished by their cytokeratin 5 (K5) and cytokeratin 8 (K8) phenotypes 30 . The ectopic thymuses were present in the subcapsular sinus of the lymph nodes (Supplementary Fig. 4 ) and contained both K5-and K8-positive regions, which correspond with thymic medullary and cortical epithelia, respectively (Fig. 3b) . We also analyzed the ectopic thymuses for the presence of recipient double-positive CD4 + CD8 + thymocytes, which represent immature T cells undergoing thymic selection 31 . The ectopic thymuses contained recipient double-positive thymocytes as well as single-positive CD4 + and CD8 + T cells, indicating a selective mechanism of T-cell commitment and maturation (Fig. 3b) .
To more fully characterize the T-cell phenotypes generated in the LN-Tx nude mice, we analyzed the T-cell receptor (TCR) repertoire by flow cytometry staining with antibodies recognizing different TCR Vβ segments (Vβ 2, Vβ 3, Vβ 4, Vβ 5.1,5.2, Vβ 6, Vβ 7, Vβ 8.1,8.2, Vβ 8.3, Vβ 9, Vβ 10 b , Vβ 11, Vβ 12, Vβ 13, Vβ 14 and Vβ 17 a ). We found each Vβ segment on the CD3 + T cells of C57BL/6 wildtype splenocytes. Heterozygous BALB/c nude mouse splenocytes expressed 10 out of the 15 Vβ segments, which is consistent with known partial or complete genetic deletions of certain Vβ segments (Vβ 3, Vβ 5.1,5.2, Vβ 9, Vβ 11 and Vβ 12) in this strain. Notably, splenocytes in LN-Tx nude recipients expressed a Vβ profile similar to that of the heterozygous BALB/c nude mice (Fig. 3c) . These results demonstrate that a C57BL/6 ectopic thymus promotes the development of T cells generated from the bone marrow of recipient BALB/c nude mice.
We then further characterized the splenic T cells in LN-Tx nude mice by flow cytometry to determine whether regulatory, naive, central memory and effector memory T cell subsets were present. We detected regulatory T cells by analyzing FoxP3 expression in CD4 + CD25 + T cells. We observed similar percentages of regulatory T cells in splenocytes from C57BL/6, heterozygous nude and LN-Tx nude mice (Fig. 3d) . We distinguished naive and memory T cells using differential expression of CD44 and CD62L (where naive cells are CD44 − CD62L + , central memory cells are CD44 + CD62L + , and effector memory cells are CD44 + CD62L − ). As with the regulatory T cells, we detected naive and memory T cell subsets among splenocytes from C57BL/6, heterozygous nude and LN-Tx nude mice (Fig. 3d) . The percentage of effector memory T cells was higher and the percentage of naive T cells was lower in the LN-Tx nude mice than in the other two groups, perhaps because these mice had been previously exposed to skin grafts (see below).
As the LN-Tx nude mice contained a range of peripheral singlepositive CD4 + and CD8 + T cells, we asked whether the de novo immune system in these recipient mice could mount a T cell-mediated response against a skin allograft. We transplanted tail skin from C57BL/6 (syngeneic with regard to the donor thymus) or CBA/CaJ (allogeneic with regard to the donor thymus) mice to the dorsal side of LN-Tx BALB/c nude mice. After 2 weeks, all of the LN-Tx BALB/c nude mice had rejected the allogeneic CBA/CaJ skin grafts. Conversely, the C57BL/6 skin grafts were all completely accepted after 2 weeks (Fig. 3e) . We then asked whether LN-Tx BALB/c nude mice would mount an immune response against a xenogeneic tumor cell transplant. We thus injected 300,000 human colorectal cancer cells 32 into the subcutaneous space of BALB/c nude and LN-Tx BALB/c nude mice. The majority (8 of 9) of the injected LN-Tx BALB/c nude mice rejected the tumors (Fig. 3e) . In contrast, xenogeneic tumors grew in the untreated BALB/c nude mice (Fig. 3e) . These results suggest that the single-positive T cells present in the LN-Tx BALB/c nude mice were functional. Together, these data support the concept of using the lymph node as a site for thymic transplant to generate an ectopic thymus. npg A r t i c l e s Functional pancreatic islets in the lymph node We then hypothesized that the lymph node might also provide a suitable environment for pancreatic islet transplantation. We harvested islets from C57BL/6 GFP + transgenic mice and transplanted them into the jejunal lymph nodes of C57BL/6 wild-type mice (LN-Tx mice) treated with streptozotocin, which induces diabetes. We monitored the blood glucose concentrations of these mice weekly, and after 6 weeks we removed the transplanted lymph nodes to analyze islet engraftment. 
A r t i c l e s
We found GFP + islets within the subcapsular sinus of the lymph nodes adjacent to the densely packed lymphocytes that are indicative of a typical lymph node (Fig. 4a) . We detected expression of C-peptide and glucagon, markers of pancreatic β-cell and α-cell function, respectively, within the engrafted lymph nodes (Fig. 4a) .
Next, we asked whether islets transplanted to the lymph nodes of diabetic mice (blood glucose concentrations greater than 300 mg/dl) are able to lower the blood glucose concentrations of the mice to a normal range (100-200 mg/dl). Similarly to islets transplanted under the kidney capsule, islets transplanted directly into the lymph nodes restored the mean blood glucose concentrations of the recipient mice to normal levels within 6 weeks after transplantation (Fig. 4b) . In three of five LN-Tx mice, a second islet transplant was performed into the jejunal lymph node 1 week after the initial transplant. The mice that did not receive a transplant all died after 3 weeks. Furthermore, normoglycemia was maintained in the one mouse examined at 6 months for at least 6 months after lymph node transplantation (data not shown). These results suggest that pancreatic islets transplanted in the lymph nodes survive and function in vivo with the capacity to sustain long-term normoglycemia.
Because we observed engraftment of multiple cell types in the lymph nodes, we asked whether activation of a lymph node-mediated immune response might interfere with the function of the engrafted cells. Therefore, we induced an inflammatory reaction in the intraperitoneal cavities of normoglycemic mice that had received islet transplants into their lymph nodes; to induce the inflammatory reaction, we injected the mice with lipopolysaccharide (LPS, 1 mg per kg of body weight). We confirmed the effective induction of inflammation by measuring the serum concentrations of tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and IL-6 ( Fig. 4c) . Immediately after LPS injection, we noted a temporary reduction in the weight and blood glucose concentrations of the mice, which completely normalized after 4 d (Fig. 4c) . We did not observe any increase in glucose concentrations above normal levels in these mice (normoglycemia was still detected 5 weeks after LPS injection). Together, these data suggest no apparent negative effect of the lymphatic or immune systems on lymph node-grafted islets. 
Vasculature of injected lymph nodes
We demonstrated that cell engraftment in the lymph node is not restricted to one cell type. This result is consistent with the current concept of metastasis to the lymph node, where multiple cancer cell types are capable of residing, and suggests that the lymph node environment is exceptionally well suited to promote the survival and function of transplanted cells in general. Because abundant vasculature is required to sustain organ function 6, 33 , we hypothesize that the dense vascular network in the lymph node is an important contributor to sustaining long-term engraftment of normal epithelial tissue. We observed dense neovascular trees in the lymph nodes into which we injected hepatocytes (Fig. 5a) . Lymph nodes injected with hepatocytes, thymic cells or islets contained many recipient-derived CD31 + endothelial cells pervading the areas of engraftment, suggesting that extensive blood-vessel remodeling took place during the ectopic tissue engraftment ( Fig. 5b and Supplementary Fig. 5 ). Moreover, we detected CD105 + (Endoglin) cells and Collagen IV + cells, which are markers of neovascular remodeling, in each of the engrafted lymph nodes (Fig. 5b) [34] [35] [36] . These data suggest that blood vessels in the surrounding lymph node environment contribute to the neovascularization and overall function of the ectopic tissues.
DISCUSSION
There are over 500 lymph nodes in the human body, many of which are relatively easily accessible. Although a single lymph node structurally limits the number of donor cells that can be transplanted, it is technically feasible to transplant more than one lymph node to gain sufficient organ or tissue function from the transplanted cells. The potential loss of function in a few lymph nodes does not seem to compromise the overall function of the lymphatic system. In fact, lymphedema is the most common complication after lymphadenectomy in patients with cancer and only affects a limited number of these patients 37 . Compression syndrome and lymphatic spread are two of the common issues in patients with cancer that have metastatic diseases in their lymph nodes. However, we found none of these complications in any of our experiments. It is also important to note that we transplanted healthy, not transformed, cells into the lymph nodes, so the intrinsic potential of the transformed cells for widespread metastatic migration and uncontrolled growth was not present in our experiments. Large animal studies will provide further insight into the potential difficulties associated with cell transplant to the lymph node.
Lymph node biopsies by fine-needle aspiration are a routine diagnostic procedure, with lymph nodes often being readily identified by palpation or ultrasound guidance. In fact, the clinical application of lymph node injection has been validated, with patients rating the procedure as less painful than venous puncture 38 . Moreover, if a less superficial node is advantageous for therapy, ultrasound guidance can be used to successfully inject the visceral mesenteric lymph nodes 39 . The strong clinical precedent of ultrasound-guided lymph node injections may help make this technique readily adaptable to a clinical setting. These minimally invasive techniques may also provide a potential therapy for patients who are ineligible for a more invasive therapy because of comorbidities.
In the treatment of liver failure, transplantation of hepatocytes into ectopic sites, including the spleen, pancreas, peritoneal cavity and subrenal capsule, has been proposed. The feasibility and efficacy of these techniques have been confirmed in preclinical studies, but clinical success rates have been limited thus far, and new methods are needed to improve hepatocyte engraftment 1, 7 . It should be noted that our goal is not to replace a whole liver but to complement liver functions by generating functional ectopic hepatic tissue. In our Fah −/− mice, we generated around 70% of the liver mass in one lymph node. The native liver is still present but at a reduced size and, probably, reduced function. For patients with liver disease, we postulate that liver function gradually deteriorates and transplantation of several lymph nodes with hepatocytes will create enough hepatic mass to stabilize the liver disease. In addition, we hypothesize that the hepatic mass generated in the lymph node may provide enough hepatic function to facilitate regeneration of the native liver. It should also be noted that transplantation of heterotopic liver has been discussed at length in the literature as a possible alternative to orthotopic liver transplantation 34, 40, 41 .
Thymus transplants have been performed exclusively in the quadriceps of pediatric patients with complete DiGeorge syndrome 4 . Unfortunately, children with DiGeorge syndrome often show poor growth, and transplantation is frequently postponed to allow for further development 42 . Furthermore, a lack of vascularization and the resulting ischemia after transplant are detrimental 43 . Transplanting thymic cells into the lymph node may represent an advantageous site to provide thymic function.
The optimal implantation site for pancreatic islet transplantation to increase function, reduce necessary implantation mass and decrease immunogenicity is still under debate 6, [44] [45] [46] . However, proximity to a good vascular supply is clearly essential for the survival of islet cells, as well as for that of hepatocytes and thymic epithelial cells.
One concern for cell transplant into the lymph node is the rapid immune response that can be initiated by the introduction of a foreign antigen into a site that is densely packed with lymphocytes. In our study, we included experiments under allogeneic conditions and blocked the T-cell response to prevent any alloreactivity. We observed that the immune reaction in the lymph nodes is not stronger or faster than the reaction in other sites and that immune suppression therapy works at a similar efficiency compared to the classic hepatocyte transplantation in the spleen. We expect that immunosuppressive therapies similar to those used in clinical organ transplants can be used with this approach.
Reprogramming somatic cells provides an exciting potential source of donor cells for regenerative medicine 47 . As these cells can be derived from autologous material and are capable of being recognized as 'self ' by the host immune system, they can potentially overcome immunologic barriers. However, recent studies have suggested that these autologous cells may not be entirely protected from the immune system 48 . On the basis of our results, the lymph node may be an effective transplantation site for reprogrammed somatic cells that can be developed for organ regeneration purposes.
In summary, we provide the first report, to our knowledge, describing the use of a lymph node as a site for functional cellular transplant. By directly injecting the lymph node with hepatocytes, thymuses or pancreatic islets, we demonstrate engraftment of the donor cells and subsequent organ function. This new approach of using the lymph node as an in vivo bioreactor in which to regenerate functional organs may be beneficial to the field of regenerative medicine.
METHODS
Methods and any associated references are available in the online version of the paper.
